p53 status, cellular recovery and cell cycle arrest as prognosticators of in vitro radiosensitivity in human pancreatic adenocarcinoma cell lines

International Journal of Radiation Biology

Volumn 75, Issue 11, 1999, Pages 1365-1376

  Ng, C E ^a   Banerjee, S K ^a   Pavliv, M ^a   Wang, G ^a   Raaphorst, G P ^a   Aubin, R A ^b  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b HEALTH CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P21; PROTEIN P53;

ARTICLE; CANCER RADIOTHERAPY; CELL CYCLE G2 PHASE; CONTROLLED STUDY; DNA REPAIR; DNA REPLICATION; HUMAN; HUMAN CELL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RADIOBIOLOGY; RADIOSENSITIVITY; X IRRADIATION;

EID: 0032701178     PISSN: 09553002     EISSN: None     Source Type: Journal    
DOI: 10.1080/095530099139241     Document Type: Article

References (72)

1. AKASHI, M., HASHIYA, M., OSAWA, Y., SPIRIN, K., SUZUKI, G. and KOEFFLER, H. P., 1995, Irradiation induces WAF1 expression through a p53-independent pathway in KG-1 cells. Journal of Biological Chemistry, 270, 19181-19187.
2. ALBOR, A., KARU, S. and KULESZ-MARTIN, M., 1998, Wild type and mutant forms of p53 activate human topoisomerase I: A possible mechanism for gain of function. Cancer Research, 58, 2091-2094.
3. ALPAN, R. S. and PARDEE, A. B., 1996, p21 WAFI/CIP1/SDI1 is elevated through a p53-independent pathway by mimosine. Cell Growth and Differentiation, 7, 893-901.
4. BARGONETTI, J., MANFREDDI, J. J., CHEN, X., MARSHAK, D. R. and PRIVES, C., 1993, A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes and Development, 7, 2565-2574.
5. BARTON, C. M., STADDON, S. L., HUGHES, C. M., HALL, P. A., O'SULLIVAN, C., KLOPPEL, G., THEIS, B., RUSSELL, R. C., NEOPTOLEMOS, J. and WILLIAMSON, R. C., 1991, Abnormalities of the p53 tumor suppressor gene in human pancreatic cancer. British Journal of Cancer, 64, 1076-1082.
6. BIARD, D. S. F., MARTIN, M., LE RHUN, Y., DUTHU, A., LEFAIX, J. L., MAY, E. and MAY, P., 1994, Concomitant p53 gene mutation and increased radiosensitivity in rat lung embryo epithelial cells during neoplastic development. Cancer Research, 54, 3361-3364.
7. BLACOSKLONNY, M. V., AN, W. G., ROMANOVA, L. Y., TREPEL, J., FOJO, T. and NECKERS, L., 1998, p53 inhibits hypoxia-inducible factor stimulated transcription. Journal of Biological Chemistry, 273, 11995-11998.
8. BOOTHMAN, D. A., WANG, M., SCHEA, R., BURROWS, H. L., STRICKFADEN, S. and OWENS, J. K., 1992, Posttreatment exposure to camptothecin enhances the lethal effects of X-rays on radioresistant human malignant melanoma cells. International Journal of Radiation Oncology, Biology, Physics, 24, 938-948.
9. BRACHMAN, D. G., BECKETT, M., GRAVES, D., HARAF, D., VOKES, E. and WEICHSELBAUM, R. R., 1993, p53 Mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Research, 53, 3667-3669.
10. BRISTOW, R. G., HU, Q., CHUNG, J. A., PEACOCK, J., BENCHIMOL, S. and HILL, R. P., 1998, Radioresistant Mtp53-expressing rat embryo cell transformants exhibit increased DNA-dsb rejoining during exposure to ionizing radiation. Oncogene, 16, 1789-1802.
11. BRISTOW, R. G., JANG, A., PEACOCK, J., CHUNG, S., BENCHIMOL, S. and HILL, R. P., 1994, Mutant p53 increases radioresistance in rat embryo fibroblasts simultaneously transfected with HPV16-E7 and/or activated H-ras. Oncogene, 9, 1527-1536.
12. CANADIAN CANCER STATISTICS, 1997 (Toronto: National Cancer Institute of Canada).
13. CANMAN, C. E., CHEN, C. Y., LEE, M. H. and KASTAN, M. B., 1994, DNA damage responses: p53 induction, cell cycle perturbations, and apoptosis. Cold Spring Harbor Symposia on Quantitative Biology, 59, 277-286.
14. CHEONG, N., WANG, Y. and ILIAKIS, G. E., 1993, Radioresistance induced in rat embryo cells by transaction with the oncogenes H-ras plus v-myc is cell cycle dependent and is maximal during S and G2. International Journal of Radiation Biology, 63, 623-629.
15. CROSS, S. M., SANCHEZ, C. A., MORGAN, C. A., SCHHIMKE, M. A., RAMEL, S., IDZERDA, R. L., RASKIND, W. H. and REID, B. J., 1995, A p53-dependent mouse spindle checkpoint. Science, 267, 1353-1356.
16. DERGHAM, S. T., DUGAN, M. C., JOSHI, U. S., CHEN, Y. C., DU, W., SMITH, D. W., ARLAUSKAS, P., CRISSMAN, J. D., VAITKEVICIUS, V. K. and SARKAR, F. H., 1997, The clinical significance of p21(WAF1/CIP1) and p53 expression in pancreatic carcinoma. Cancer, 80, 372-381.
17. DITTMER, D., PATI, S., ZAMBETTI, G., CHU, S., TERESKY, A. K., MOORE, M., FINLAY, C. and LEVINE, A. J., 1993, p53 gain of function mutations. Nature Genetics, 4, 42-46.
18. EL-DEIRY, W. S., TOKINO, T., VELCULESCU, V. E., LEVY, D. B., PARSONS, R., TRENT, J. M., LIN, D., MERCER, W. E., KINZLER, K. W. and VOGELSTEIN, B., 1993, WAF1, a potential mediator of p53 tumor suppression. Cell, 75, 817-825.
19. FAN, S., EL-DEIRY, W. S., BAE, I., FREEMAN, J., JONDLE, D., BHATTA, K., FORNACE, A. J., MAGRATH, I., KOHN, K. W. and O'CONNOR, P. M., 1994, p53 Gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Research, 54, 5824-5830.
20. FREGEAU, C. J., AUBIN, R. A., ELLIOTT, J. C., GILL, S. S. and FOURNEY, R. M., 1995, Characterization of human lymphoid cell lines GM9947 and GM9948 as intra-and inter-laboratory reference standards for DNA typing. Genomics, 28, 184-197.
21. HALL, E. J., 1994, Radiobiology for the Radiologist, 4th edn (Philadelphia: Lippincott).
22. HARPER, J. W., ADAMI, G. R., WEI, N., KEYOMARSI, K. and ELLEDGE, S. J., 1993, The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin dependent kinases. Cell, 75, 805-816.
23. HARRIS, C. C., 1996, Structure and function of the p53 tumor supressor gene: clues for rational cancer therapeutic strategies. Journal of the National Cancer Institute, 88, 1442-1455.
24. HARTWELL, L. and KASTAN, M. B., 1994, Cell cycle control and cancer. Science, 266, 1821-1828.
25. HENDRY, J. H., CAI, W. B., ROBERTS, S. A. and POTTEN, C. S., 1997, p53 deficiency sensitizes clonogenic cells to irradiation in the large but not the small intestine. Radiation Research, 148, 254-259.
26. HIRAI, A., BOLD, R. J., ISHIZUKA, J., HIRAI, M., TOWNSEND, C. M. and THOMPSON, J. C., 1996, Hyperphosphorylation of retinoblastoma protein and stimulation of growth by okadaic acid in human pancreatic cancer. Digestive Diseases and Science, 41, 1975-1980.
27. HOLLSTEIN, M., SIDRANSKY, D., VOGELSTEIN, B. and HARRIS, C. C., 1991, p53 Mutations in Human Cancers. Science, 253, 49-53.
28. JACKS, T. and WEINBERG, R. A., 1996, Cell cycle control and its watchmen. Nature, 381, 643-644.
29. JOHNSON, M., DIMITROV, D., VOLTA, P. J., BARRETT, J. C., NODA, A., PEREIRA-SMITH, O. M. and SMITH, J. R., 1994, Evidence for a p53-independent pathway for up-regulation of SDI1/CIP1/WAF1/p21 RNA. Molecular Carcinogens, 11, 59-64.
30. JUNG, J., NOTARIO, V. and DRITSCHILO, A., 1992, Mutations in the p53 gene in radiation-sensitive and -resistant human squamous carcinoma cells. Cancer Research, 52, 6390-6393.
31. KASTAN, M. B., ONYEKWERE, O., SIDRANSKY, D., VOGELSTEIN, B. and CRAIG, R. W., 1991, Participation of p53 protein in the cellular response to DNA damage. Cancer Research, 51, 6304-6311.
32. KIM, J. H., KIM, S. H., KOLOZSVARY, A. and KHIL, M. S., 1992, Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan. International Journal of Radiation Oncology, Biology, Physics, 22, 515-518.
33. KO, L. J. and PRIVES, C., 1996, p53 puzzle and paradigm. Genes and Development, 10, 1054-1072.
34. KUERBITZ, S. J., PLUNKETT, B. S., WALSH, W. V. and KASTAN, M. B., 1992, Wild type p53 is a cell cycle checkpoint determinant following irradiation. Proceedings of the National Academy Sciences, USA, 89, 7491-7495.
35. LEE, J. M. and BERNSTEIN, A., 1993, p53 mutations increase resistance to ionizing radiation. Proceedings of the National Academy of Sciences, USA, 90, 5742-5746.
36. LEVINE, A. J., 1997, p53, the cellular gatekeeper for growth and division. Cell, 88, 323-331.
37. LI, C. Y., NAGASAWA, H., DAHLENBERG, W. K. and LITTLE, J. B., 1995, Diminished capacity for p53 in mediating a radiation-induced G1 arrest in established human tumor cell lines. Oncogene, 11, 1885-1892.
38. LING, C. C., GUO, M., CHEN, C. H. and DELOHEREY, T., 1995, Radiation-induced apoptosis: effects of cell age and dose fractionation. Cancer Research, 55, 5207-5212.
39. LIONETTO, R., PUGLIESE, V., BRUZZI, P. and ROSSO, R., 1995, No standard treatment is available for advanced pancreatic cancer. European Journal of Cancer, 31A, 882-887.
40. LITTLE, J. B. and NAGASAWA, H., 1985, Effect of confluent holding on potentially lethal damage repair, cell cycle progression and chromosomal aberrations in human normal and ataxia-telangiectasia fibroblasts. Radiation Research, 101, 81-93.
41. LOIGNON, M., FETNI, R., GORDON, A. J. E. and DROBETSKY, E. A., 1997, A p53-independent pathway for induction of p21 waf1/cip1 and concomitant G1 arrest in UV-irradiated human skin fibroblast. Cancer Research, 57, 3390-3394.
42. LOWE, S. W., RULEY, H. E., JACKS, T. and HOUSMAN, D. E., 1993a, p53 dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74, 957-967.
43. LOWE, S. W., SCHMITT, E. M., SMITH, S. W., OSBORNE, B. A. and JACKS, T., 1993b, p53 is required for radiation-induced apoptosis in mouse thymocytes, Nature, 362, 847-849.
44. LYNCH, H. T., SMYRK, T., KERN, S. E., HRUBAN, R. H., LIGHTDALE, C. J., LEMON, S. J., LYNCH, J. F., FUSARO, L. R., FUSARO, R. M. and GHADIRIAN, P., 1996, Familial pancreatic cancer: a review. Seminars in Oncology, 23, 251-275.
45. MCILWRATH, A. J., VASEY, P. A., ROSS, G. M. and BROWN, R., 1994, Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Research, 54, 3718-3722.
46. MCLEOD, H. L. and KEITH, W. N., 1996, Variation in topoisomerase T gene copy number as a mechanism for intrinsic drug sensitivity. British Journal of Cancer, 74, 508-512.
47. MIRZAYANS, R., AUBIN, R. A., BOSNICH, W., BLATTNER, W. A. and PATERSON, M. C., 1995, Abnormal pattern of post-gamma-ray DNA replication in radioresistant fibroblast strains from affected members of a cancer-prone family with Li-Fraumeni syndrome. British Journal of Cancer, 71, 1221-1230.
48. MUSK, S. R. R. and STEEL, G. G., 1990, The inhibition of cellular recovery in human tumor cells by inhibitors of topoisomerase. British Journal of Cancer, 62, 364-367.
49. NG, C. E., BUSSEY, A. M. and RAAPHORST, G. P., 1994, Inhibition of potentially lethal and sublethal damage repair by camptothecin and etoposide in human melanoma cell lines. International Journal of Radiation Biology, 66, 49-57.
50. NG, C. E., MURADIA, G., CYBULSKI, S. E., BUSSEY, A. M., LEE, J. F., RAAPHORST, G. P. and AUBIN, R. A., 1997, Expression of mutant p53 modulates sensitivity to etoposide in human pancreatic tumor cell lines. In 54th Annual Radiation Research Society Meeting, Providence, Rhode Island, abst 176.
51. O'CONNOR, P. M., JACKMAN, J., BAE, I., MYERS, T. G., FAN, S., MUTOH, M., SCUDIERO, D. A., MONKS, A., SAUSVILLE, E. A., WEINSTEIN, J. N., FRIEND, S., FORNACE, A. J. and KOHN, K. W., 1997, Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute Anticancer Drug Screen and correlations with the growth inhibitory potency of 123 anticancer agents. Cancer Research, 57, 4285-4300.
52. O'CONNOR, P. M., JACKMAN, J., JONDLE, D., BHATTA, K., MAGRATH, I. and KOHN, K. W., 1993, Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Research, 53, 4776-4780.
53. POMMIER, Y., 1996, Eukaryotic DNA topo I: genome gatekeeper and its intruders, camptothecin. Seminars in Oncology, 23, 3-10.
54. RIBIERO, J. C. C., BARNETSON, A. R., FISHER, R. J., MAMEGHAN, H. and RUSSELL, P. J., 1997, Relationship between radiation response and p53 status in human bladder cancer cells. International Journal of Radiation Biology, 72, 11-20.
55. RUDOLTZ, M. S., BLANK, K. R., KAO, G., MUSCHEL, R. J. and MCKENNA, W. G., 1996, Ionizing radiation and the cell cycle. Radiation Oncology Investigation, 4, 147-158.
56. RUGGIERI, B., ZHANG, S. Y., CAAMANO, J., DIRADO, M., FLYNN, S. D. and KLEIN-SZANTO, A. J., 1992, Human pancreatic carcinoma and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor suppressor genes. Oncogene, 7, 1503-1511.
57. SCHWARTZ, J. L., COWAN, J., GRDINA, D. J. and WEICHSELBAUM, R. R., 1996, Attenuation of G2 phase cell cycle checkpoint control is associated with increasing frequency of unrejoined chromosome breaks in human tumor cells. Radiation Research, 146, 139-143.
58. SIDDIK, Z. H., MIMS, B., LOZANO, G. and THAI, C., 1998, Independent pathways of p53 induction by cisplatin and X-radiation in a cisplatin resistant ovarian tumor cell line. Cancer Research, 58, 698-703.
59. SLICHENMYER, W. J., NELSON, W. G., SLEBOS, R. J. and KASTAN, M. B., 1993, Loss of p53-associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Research, 53, 4164-4168.
60. SMITH, M. L., CHEN, I. T., ZHAN, Q. and BAE, I., 1994, Interaction of the p53-regulated protein GADD45 with proliferating cell nuclear antigen. Science, 266, 1376-1380.
61. SU, L. N. and LITTLE, J. B., 1993, Prolonged cell cycle delay in radioresistant human cell lines transacted with activated ras oncogene and/or simian virus 40 T-antigen. Radiation Research, 133, 73-79.
62. THOMAS, P. R. M., 1996, Radiotherapy for carcinoma of the pancreas. Seminars in Oncology, 23, 213-219.
63. WALDMAN, T., KINZLER, K. W. and VOGELSTEIN, B., 1995, p21 is necessary for the p53 mediated G1 arrest in human cancer cells. Cancer Research, 55, 5187-5190.
64. WALDMAN, T., LENGAUER, C., KINZLER, K. W. and VOGELSTEIN, B., 1996, Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature, 381, 713-716.
65. WEINERT, T. A. and HARTWELL, L. H., 1988, The Rad9 gene controls the cell cycle response to DNA damage in Saccharomyces cerevisiae. Science, 241, 317-322.
66. WENZ, F., YU, Y., NAGASAWA, H., IMRICH, A. C., KENG, P. C. and LITTLE, J. B., 1997, Lack of uncoupling of S-phase and mitosis after irradiation in p53-human lymphoblast cell lines. Radiation Research, 148, 129-134.
67. WITHOFF, S., DE JONG, S., DE VRIES, E. G. E. and MULDER, N. H., 1996a, Human DNA topoisomerase II: biochemistry and role in chemotherapy resistance [Review]. Anticancer Research, 16, 1867-1880.
68. WITHOFF, S., KEITH, W. N., KNOL, A. J., COUTTS, J. C., HOARE, S. F., MULDER, N. H. and DE VRIES, E. G. E., 1996b, Selection of a subpopulation with fewer DNA topoisomerase II alpha gene copies in a doxorubicin-resistant cell line panel. British Journal of Cancer, 74, 502-507.
69. WOUTERS, B. G., GIACCIA, A. J., DENKO, N. C. and BROWN, J. M., 1997, Loss of p21/waf1/cip1 sensitizes tumors to radiation by an apoptosis-independent mechanism. Cancer Research, 57, 4703-4706.
70. YONISH-ROUACH, E., RESNITZKY, D., LOTEM, J., SACHS, I., KIMCHI, A. and OREN, M., 1991, Wild type p53 induces apoptosis of mycloid leukemia cells that is inhibited by interleukin-6. Nature, 352, 345-347.
71. ZANIER, R., DE SALVIA, R., FIORE, M. and DEGRASSI, F., 1996, Topoisomerase I activity and cellular response to radiation in Chinese hamster cells. International Journal of Radiation Biology, 70, 251-259.
72. ZHAN, Q., CARRIER, F. and FORNACE, A. J., 1993, Induction of cellular p53 activity by DNA-damaging agents and growth arrest. Molecular and Cellular Biology, 13, 4242-4250.